Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 5:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 216 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Definitive Surgery Clear all
Terminated Phase 2 Interventional Results available

Phase II Trial of Neoadjuvant Metronomic Chemotherapy in Triple-Negative Breast Cancer

NCT00542191
View directory record Official record
Conditions
Breast Cancer
Interventions
Doxorubicin / Cyclophosphamide / Paclitaxel / Carboplatin, Definitive Surgery, Radiotherapy
Drug · Procedure · Radiation
Lead sponsor
Leo W. Jenkins Cancer Center
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated May 26, 2021 · Synced Oct 29, 2026, 5:45 AM EDT
Recruiting Phase 3 Interventional

Antibiotic Cement Bead Pouch Versus Negative Pressure Wound Therapy

NCT05615844
View directory record Official record
Conditions
Open tíbia Fracture
Interventions
Antibiotic Cement Bead Pouch, Negative Pressure Wound Therapy
Drug · Device
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
30
States / cities
Chandler, Arizona • Tucson, Arizona • Davis, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 29, 2026, 5:45 AM EDT
Completed Phase 1 Interventional

hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse

NCT02960594
View directory record Official record
Conditions
Breast Cancer, Lung Cancer, Pancreatic Cancer, Head and Neck Cancer, Ovarian Cancer, ColoRectal Cancer, Gastric Cancer, Esophageal Cancer, HepatoCellular Carcinoma
Interventions
INO-1400, INO-9012, INO-1401
Biological
Lead sponsor
Inovio Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
6
States / cities
Detroit, Michigan • Rochester, Minnesota • Chapel Hill, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2018 · Synced Oct 29, 2026, 5:45 AM EDT
Recruiting Phase 2 Interventional

Three Schedules of CUE-101 Administered Before Surgery or Definitive Chemoradiation Therapy in HLA-A*0201 Positive Patients With Locally Advanced, HPV16-Positive Oropharyngeal Squamous-Cell Carcinoma

NCT04852328
View directory record Official record
Conditions
Oropharyngeal Squamous Cell Carcinoma
Interventions
CUE-101
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 29, 2026, 5:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Fabrication of a Definitive Cad/Cam Titanium Abutment Prior to Guided Surgery: a Pilot Study.

NCT02218541
View directory record Official record
Conditions
Single Edentulous Space
Interventions
abutment margin 0.5 mm subgingival, abutment margin 1.5 mm subgingival
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 99 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 27, 2018 · Synced Oct 29, 2026, 5:45 AM EDT
Terminated Phase 2 Interventional Results available

A Study of Vorinostat and Tamoxifen in Newly Diagnosed Breast Cancer

NCT01194427
View directory record Official record
Conditions
Stage I Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer, Invasive Breast Cancer
Interventions
Vorinostat and Tamoxifen
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 17, 2013 · Synced Oct 29, 2026, 5:45 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer

NCT04929392
View directory record Official record
Conditions
Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Pathologic Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IC Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8
Interventions
Carboplatin, Endoscopic Biopsy, External Beam Radiation Therapy, Lenvatinib Mesylate, Paclitaxel, Pembrolizumab, Resection
Drug · Procedure · Radiation + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 29, 2026, 5:45 AM EDT
Recruiting No phase listed Observational

Study of ICG Fluorescence Imaging in Open Fracture and Infection Patients

NCT06793644
View directory record Official record
Conditions
Fractures, Bone, Trauma Injury
Interventions
Immunofluorescence Imaging
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 29, 2026, 5:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Impact of Gum Infection on Heart Disease

NCT00093236
View directory record Official record
Conditions
Cardiovascular Disease, Periodontal Disease
Interventions
Early Periodontal Treatment, Usual Dental Hygiene
Procedure
Lead sponsor
Boston University
Other
Eligibility
20 Years and older
Enrollment
174 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 20, 2017 · Synced Oct 29, 2026, 5:45 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone

NCT02736123
View directory record Official record
Conditions
Melanoma
Interventions
Nivolumab - Arm A, Nivolumab + Ipilimumab - Arm B
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 20, 2017 · Synced Oct 29, 2026, 5:45 AM EDT
Suspended No phase listed Observational Accepts healthy volunteers

Evaluating the Bacterial and Fungal Microbiome in Patients With Calcium Oxalate Urolithiasis and Renal Cell Carcinoma

NCT04669860
View directory record Official record
Conditions
Calcium Oxalate Urolithiasis, Renal Cell Carcinoma
Interventions
Not listed
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2029
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 29, 2026, 5:45 AM EDT
Completed Not applicable Interventional Results available

Pre-Surgical Intervention for Targeted Therapies for Breast Cancer

NCT01004744
View directory record Official record
Conditions
Invasive Breast Cancer
Interventions
Anastrozole
Drug
Lead sponsor
Columbia University
Other
Eligibility
21 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 11, 2021 · Synced Oct 29, 2026, 5:45 AM EDT
Completed Phase 1 Interventional Results available

Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

NCT01798004
View directory record Official record
Conditions
Ganglioneuroblastoma, Stage 1 Neuroblastoma, Stage 2 Neuroblastoma, Stage 2A Neuroblastoma, Stage 2B Neuroblastoma, Stage 3 Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Busulfan, Cisplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, External Beam Radiation Therapy, Filgrastim, Laboratory Biomarker Analysis, Melphalan, Mesna, Peripheral Blood Stem Cell Transplantation, Pharmacological Study, Topotecan Hydrochloride, Vincristine Sulfate
Procedure · Drug · Radiation + 2 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 30 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2024
U.S. locations
113
States / cities
Birmingham, Alabama • Downey, California • Duarte, California + 90 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2024 · Synced Oct 29, 2026, 5:45 AM EDT
Completed Phase 2 Interventional Results available

Paclitaxel, Cyclophosphamide & Doxorubicin, Autologous Dendritic Cells & Surgery in Stage II/III Breast Cancer (Women)

NCT00499083
View directory record Official record
Conditions
Breast Cancer
Interventions
therapeutic autologous dendritic cells, aromatase inhibition therapy, cyclophosphamide, doxorubicin hydrochloride, paclitaxel, tamoxifen citrate, gene expression analysis, protein expression analysis, reverse transcriptase-polymerase chain reaction, immunoenzyme technique, immunohistochemistry staining method, laboratory biomarker analysis, adjuvant therapy, biopsy, conventional surgery, neoadjuvant therapy, radiation therapy
Biological · Drug · Genetic + 3 more
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 120 Years · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
2
States / cities
Tampa, Florida • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 29, 2023 · Synced Oct 29, 2026, 5:45 AM EDT
Active, not recruiting Phase 2 Interventional

Partial Breast Irradiation (PBI) Using 40 Gy for Select Patients With Early Invasive or Noninvasive Breast Cancer

NCT01203839
View directory record Official record
Conditions
Breast Cancer
Interventions
multiple beams utilizing either intensity-modulated or 3D-conformal techniques
Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2027
U.S. locations
8
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 29, 2026, 5:45 AM EDT
Terminated Phase 2 Interventional Results available

Pembrolizumab in HNSCC With Residual Disease After Radiation

NCT02892201
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
Pembrolizumab
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
2
States / cities
New Haven, Connecticut • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Oct 29, 2026, 5:45 AM EDT
Terminated Phase 4 Interventional Results available

The Duration of Antibiotic Therapy for Early (DATE) Ventilator Associated Pneumonia (VAP): 4 vs. 7 Days

NCT05545735
View directory record Official record
Conditions
Ventilator Associated Pneumonia
Interventions
Standard of Care Antibiotic Therapy
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 16, 2026 · Synced Oct 29, 2026, 5:45 AM EDT
Not listed No phase listed Observational

Radiostereometric Analysis of Spine Arthrodesis

NCT01721889
View directory record Official record
Conditions
Lumbar Degenerative Disc Disease
Interventions
Radiostereometric Analysis
Radiation
Lead sponsor
OAD Orthopaedics
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Warrenville, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 11, 2013 · Synced Oct 29, 2026, 5:45 AM EDT
Active, not recruiting Phase 2 Interventional

Selective Avoidance of Nodal VolumEs at Minimal Risk (GCC 20110)

NCT04609280
View directory record Official record
Conditions
Head and Neck Cancer, Oropharynx Cancer, Oropharyngeal Squamous Cell Carcinoma
Interventions
Intensity modulated radiotherapy (IMRT)/volumetric modulated arc therapy (VMAT) or Pencil beam proton therapy (PBPT)
Radiation
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
6
States / cities
Baltimore, Maryland • Bel Air, Maryland • Columbia, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 29, 2026, 5:45 AM EDT
Completed Phase 2 Interventional Results available

Carboplatin, Abraxane, Avastin as Neoadjuvant Therapy for Her2-Negative Breast Cancer

NCT00723125
View directory record Official record
Conditions
Breast Cancer
Interventions
Abraxane, Carboplatin, Avastin
Drug
Lead sponsor
William Sikov MD
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
5
States / cities
Bridgeport, Connecticut • New Haven, Connecticut • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Apr 29, 2021 · Synced Oct 29, 2026, 5:45 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Consolidative Local Therapy (CLT) in Oligo-metastatic Urothelial Carcinoma

NCT07048457
View directory record Official record
Conditions
Locally Advanced Urothelial Carcinoma, Oligo-metastaic Urothelial Carcinoma
Interventions
Radical cystectomy
Procedure
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
2
States / cities
New Haven, Connecticut • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 29, 2026, 5:45 AM EDT
Completed Phase 2 Interventional Results available

Pembrolizumab With and Without Radiotherapy for Non-Small Cell Lung Cancer

NCT03217071
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Pembrolizumab, stereotactic radiation therapy (SRT), Surgery (Non-interventional, standard of care)
Drug · Radiation · Procedure
Lead sponsor
Sue Yom
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 23, 2024 · Synced Oct 29, 2026, 5:45 AM EDT
Terminated Not applicable Interventional

Measurement of the Partial Pressure of Oxygen in Cutaneous Tumors Using Electron Paramagnetic Resonance (EPR) Oximetry

NCT03716193
View directory record Official record
Conditions
Skin Lesion, Skin Cancer, Skin Melanoma, Tumor Skin
Interventions
Oxygen
Other
Lead sponsor
West Virginia University
Other
Eligibility
18 Years to 90 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 29, 2026, 5:45 AM EDT
Completed Phase 3 Interventional Results available

Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor

NCT00945009
View directory record Official record
Conditions
Adult Kidney Wilms Tumor, Beckwith-Wiedemann Syndrome, Childhood Kidney Wilms Tumor, Diffuse Hyperplastic Perilobar Nephroblastomatosis, Rhabdoid Tumor of the Kidney, Stage I Kidney Wilms Tumor, Stage II Kidney Wilms Tumor, Stage III Kidney Wilms Tumor, Stage IV Kidney Wilms Tumor, Stage V Kidney Wilms Tumor
Interventions
Dactinomycin, Doxorubicin Hydrochloride, Radiation Therapy, Therapeutic Conventional Surgery, Vincristine Sulfate
Biological · Drug · Radiation + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 29 Years
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2026
U.S. locations
146
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 111 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 29, 2026, 5:45 AM EDT